Short Interest in Equillium, Inc. (NASDAQ:EQ) Rises By 33.3%

Equillium, Inc. (NASDAQ:EQGet Rating) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 865,300 shares, an increase of 33.3% from the March 15th total of 648,900 shares. Currently, 4.7% of the company’s stock are short sold. Based on an average daily trading volume, of 50,600 shares, the short-interest ratio is currently 17.1 days.

A number of equities analysts have recently commented on the company. Stifel Nicolaus reissued a “buy” rating and set a $12.00 price objective on shares of Equillium in a research report on Friday, March 25th. SVB Leerink lowered their price target on shares of Equillium from $18.00 to $14.00 and set an “outperform” rating for the company in a report on Wednesday, January 5th. HC Wainwright raised their price objective on shares of Equillium from $12.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, March 24th. Finally, Zacks Investment Research downgraded shares of Equillium from a “buy” rating to a “hold” rating in a research note on Wednesday, March 30th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from, Equillium currently has an average rating of “Buy” and a consensus price target of $11.75.

Shares of Equillium stock opened at $2.98 on Monday. The company has a current ratio of 9.35, a quick ratio of 9.35 and a debt-to-equity ratio of 0.13. Equillium has a 52 week low of $2.85 and a 52 week high of $7.75. The firm’s 50 day moving average is $3.46 and its two-hundred day moving average is $4.42.

Equillium (NASDAQ:EQGet Rating) last issued its earnings results on Wednesday, March 23rd. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.01). On average, sell-side analysts anticipate that Equillium will post -1.4 EPS for the current year.

In related news, CFO Jason A. Keyes sold 8,000 shares of the company’s stock in a transaction that occurred on Monday, April 4th. The shares were sold at an average price of $3.18, for a total transaction of $25,440.00. Following the sale, the chief financial officer now directly owns 23,296 shares of the company’s stock, valued at approximately $74,081.28. The sale was disclosed in a legal filing with the SEC, which is available through this link. 32.70% of the stock is owned by corporate insiders.

Several hedge funds have recently modified their holdings of the business. Geode Capital Management LLC boosted its holdings in shares of Equillium by 2.4% in the third quarter. Geode Capital Management LLC now owns 154,185 shares of the company’s stock valued at $1,051,000 after acquiring an additional 3,603 shares during the period. Dimensional Fund Advisors LP purchased a new stake in Equillium in the 4th quarter valued at $38,000. Citadel Advisors LLC purchased a new stake in Equillium in the 3rd quarter valued at $74,000. Two Sigma Securities LLC acquired a new stake in Equillium during the 3rd quarter worth $573,000. Finally, Victory Capital Management Inc. grew its position in Equillium by 4.9% during the 4th quarter. Victory Capital Management Inc. now owns 3,325,050 shares of the company’s stock worth $12,469,000 after purchasing an additional 154,851 shares during the last quarter. 28.16% of the stock is currently owned by institutional investors.

About Equillium (Get Rating)

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis.

Featured Articles

Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with's FREE daily email newsletter.